Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
    Technology 4/15/2021

    At a glance
    In this general discussion post, the primary subjects mentioned are the tone is 😐 neutral.

    Other terms

    The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
    View this post in the Community →

    Similar Community Posts Join

    5 / 388 results

    Related Research

    6 / 1000+ results